Previous 10 | Next 10 |
Pacira BioSciences (NASDAQ: PCRX ) is up 1.9% postmarket after word it's joining the S&P SmallCap 600 . More news on: Pacira BioSciences, Inc., Shutterfly, Inc., Healthcare stocks news, Stocks on the move Read more ...
PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc . (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of its Phase 3 study of EXPAREL ® (bupivacaine liposome injectable s...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
Pacira BioSciences, Inc. (PCRX) Q2 2019 Results Earnings Conference Call August 08, 2019, 08:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - CEO and Chairman Max Reinhardt - President Richard Scranton - Chief Medical Officer Charles Reinhart - CFO Conf...
Pacira Pharmaceuticals ( PCRX ) Q2 results : Revenues: $102.6M (+22.0%); Exparel sales: $98.9M (+23.0%); Iovera: $2M; Royalty revenue: $0.8M (+100.0%). More news on: Pacira BioSciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Pacira Pharmaceuticals (NASDAQ: PCRX ): Q2 Non-GAAP EPS of $0.41 beats by $0.07 ; GAAP EPS of $0.06 misses by $0.08 . More news on: Pacira BioSciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain managemen...
PARSIPPANY, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2019 Wedbush Pacgrow Healthcare Conference at 12:45 PM ET on Tuesday, August 13, 2019. Live audio of the event can be accessed by visiting the “E...
PARSIPPANY, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 8, 2019. Following the release, the company will host a live conference...
PARSIPPANY, N.J., June 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced results of a new analysis of patients undergoing elective third molar (“wisdom teeth”) extraction with at least one bony mandibular (impacted) tooth. Patients who receiv...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
2024-04-23 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 11:15:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Underperform. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-04-09 11:15:02 ET Wedbush analyst issues BUY recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...